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Abstract
Background: Mortality rates for advanced lung cancer have not declined for decades, even with the
implementation of novel chemotherapeutic regimens or the use of tyrosine kinase inhibitors. Cancer Stem Cells
(CSCs) are thought to be responsible for resistance to chemo/radiotherapy. Therefore, targeting CSCs with novel
compounds may be an effective approach to reduce lung tumor growth and metastasis. We have isolated and
characterized CSCs from non-small cell lung cancer (NSCLC) cell lines and measured their telomerase activity,
telomere length, and sensitivity to the novel telomerase inhibitor MST312.
Results: The aldehyde dehydrogenase (ALDH) positive lung cancer cell fraction is enriched in markers of stemness
and endowed with stem cell properties. ALDH+ CSCs display longer telomeres than the non-CSC population.
Interestingly, MST312 has a strong antiproliferative effect on lung CSCs and induces p21, p27 and apoptosis in the
whole tumor population. MST312 acts through activation of the ATM/pH2AX DNA damage pathway (short-term
effect) and through decrease in telomere length (long-term effect). Administration of this telomerase inhibitor (40
mg/kg) in the H460 xenograft model results in significant tumor shrinkage (70% reduction, compared to controls).
Combination therapy consisting of irradiation (10Gy) plus administration of MST312 did not improve the
therapeutic efficacy of the telomerase inhibitor alone. Treatment with MST312 reduces significantly the number of
ALDH+ CSCs and their telomeric length in vivo.
Conclusions: We conclude that antitelomeric therapy using MST312 mainly targets lung CSCs and may represent a
novel approach for effective treatment of lung cancer.
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Background
Each year, lung cancer is responsible for over 200,000
deaths in the USA [1]. Standard treatments include sur-
gical resection, radiotherapy and chemotherapy.
Although patients present an initial response to treat-
ment, tumors often relapse leading to a 5-year survival
rate of about 15%. Chemotherapeutic drugs most effi-
ciently target the tumor bulk, but a smaller fraction of
cells tend to exhibit robust resistance, which has been
attributed to the presence of cancer stem cells (CSCs)
[2]. The CSC hypothesis has recently received massive
attention, particularly because it defines CSCs as the
tumor initiating cells [3] with the ability to survive
initial treatment and give rise to tumor recurrence and
promote metastasis [4].
CSCs have been isolated using a variety of stem cell
markers and phenotypes, although their reliability appears
to depend on tumor type. In non-small cell lung cancer,
CD133 has recently been reported to identify tumor-initi-
ating cells [5] but other studies conducted in various solid
tumors demonstrated that CD133 negative cells possess
similar tumorigenic activity, suggesting that CD133 is not
an optimal marker for the isolation of CSCs [6,7]. The side
population (SP) phenotype, conferred by the ability of
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has also been shown to define cells with stem cell proper-
ties in NSCLC cell lines [8]. ABCG2, a stem cell marker of
a variety of tissues, proved to be the transporter responsi-
ble for the multidrug-resistance phenotype in isolated SP
cells [9]. However, Meng et al.,d e m o n s t r a t e dt h a tu pt o
45% of cells in NSCLC and SCLC cell lines show tumori-
genic potential, regardless of the SP phenotype and CD133
expression [7]. Measurement of aldehyde dehydrogenase
(ALDH) activity recently offered a more promising avenue.
ALDHs form a group of NAD(P)+ dependent enzymes
involved in the oxidation of aldehydes and production of
retinoic acid [10] that is thought to participate in cellular
differentiation and stem cell self-protection [11]. Normal
stem cells were shown to contain higher levels of ALDH
activity than their more differentiated progeny [12]. ALDH
activity and expression are elevated in several tumor types
including brain, breast, liver, colon, pancreas and, more
r e c e n t l y ,l u n g[ 1 3 ] .O v e r a l l ,i s o l a t i o no fA L D Hp o s i t i v e
cells from these tumors has been shown to enrich for
tumor initiating cells [14] with increased proliferation rate,
migration and adhesion ability, and more recently with
metastatic potential in the case of breast cancer [15].
Telomeres protect chromosomes from degradation,
irregular recombination and end-to-end fusions [16].
Telomeres decrease in length with every cell division
[17] until they reach a critical size [18]. In normal cells,
critically short telomeres are recognized by the DNA
damage response (DDR) and cells undergo either senes-
cence or apoptosis [19]. Tumor cells are able to over-
come senescence by expressing telomerase, an
enzymatic complex that consists of three subunits: the
Telomerase Reverse Transcriptase (TERT), the Telomer-
ase RNA Component (TERC) and the dyskerin protein
(DKC1) [20]. Telomerase protects telomeres from criti-
cal shortening, thus allowing continuous cell division
[21], and increased telomerase expression has been com-
monly found in lung cancer [22]. Therefore, because
tumor resistance and recurrence have been attributed to
the inability of chemotherapeutic drugs to eliminate
CSCs, targeting telomerase function might provide a
novel and promising approach to specifically eradicate
these cells. After thorough characterization of the lung
CSC phenotype, the aim of this study was to determine
whether antitelomeric therapy effectively targets the
CSC population both in vitro and in vivo.
Results
ALDH activity of lung cancer cell lines correlates with
stem cell properties
We initially analyzed the ALDH+ population of the
H1299 and H460 NSCLC cell lines. FACS analysis
revealed a clear ALDH+ population that was blocked by
co-incubation with the specific enzyme inhibitor DEAB.
Average percentages of ALDH+ cells were 7.57 ± 3.64%
for H1299 cells, and 1.96 ± 0.83% for H460 cells; repre-
sentative FACS images are shown in Figure 1A.
To determine if the ALDH+ fraction displayed stem
cell properties, we sorted both positive and negative
populations from the H1299 cell line and cultured
equal numbers of cells in adherent conditions for 10
days. In all cases, we found that only ALDH+ cells
were able to generate both the ALDH- and the ALDH
+ populations (Figure 1B). Similar findings were
observed for H460 cells (see additional file 1, Supple-
mentary figure 1A).
Analysis of the H1299 ALDH+ fraction by MTT
revealed an increased proliferative rate of ALDH + cells
as compared to the negative fraction, a difference that
reached statistical significance at 96 h (p < 0.05) (Figure
1C). To evaluate the in vitro malignancy, we looked at
the anchorage-independent growth of sorted cells in soft
agar. H1299 ALDH+ cells exhibited a two-fold increase
in colony formation ability as compared to the negative
population (p < 0.05), suggesting a more malignant phe-
notype (Figure 1D). Overall, these findings confirm the
presence of ALDH activity in the CSC population,
which correlates with stem cell features.
Finally, we investigated the in vivo tumorigenic poten-
tial of ALDH cells after injection into mice. As the
ALDH+ population isolated from H1299 cells was pre-
viously shown to be more tumorigenic than the negative
counterpart [23], we focused our study on the H460 cell
line. When cultured in stem cell medium (containing
EGF, bFGF and B27 supplement), H460 cells displayed a
three-fold increase in the percentage of positive cells,
further confirming their stem cell properties (Figure
2A). We thus used these cells for sorting and found a
greater tumor initiating capacity upon injection of
ALDH+ cells. Indeed, 3/3 mice presented a tumor mass
with a mean tumor volume of 46 ± 15 mm
3, while only
1/3 mice developed a small tumor after injection of the
negative population (with a tumor volume of 4 mm
3)
(Figure 2B and 2C).
Phenotypic characterization of the ALDH+ population
from NSCLC cells
As the side population (SP) phenotype has been pro-
posed to serve as a stem cell marker in lung cancer
cells, we sought to explore more thoroughly the overlap
between the SP and ALDH-populations. We identified
an SP fraction in H1299 cells of about 2.5%, that was
blocked by co-incubation with the ABCG2 inhibitor
FTC, confirming that this transporter participates in the
SP phenotype of NSCLC. A similar SP fraction was
identified in H460 cells (not shown). We next tested the
clonogenic capacity of the SP-enriched cell fraction
compared to the negative fraction. Indeed, cells within
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than the negative population for both cell lines (Figure
2D and additional file 1, Supplementary figure 1B). To
determine if the SP overlapped with the ALDH+ frac-
tion, we performed double staining for Hoechst and
ALDH using H1299 cells. Since BAAA is a substrate for
ABC transporters and because the Aldefluor buffer con-
tains inhibitors of these pumps, we first sorted SP and
non-SP cells and then analyzed both populations by
Aldefluor. SP cells were highly positive for ALDH: up to
27.3% of the cells were located in the ALDH+ area, as
compared to 3.48% for the non-SP cells (see additional
file 1, Supplementary figure 1C).
Q-RT-PCR for genes proposed to represent the CSCs
population was further analyzed. As expected, cells
sorted for ALDH expressed higher levels of this enzyme
(Figure 2E). A two-fold increase in ABCG2 expression
in ALDH+ cells as compared to the negative population
was noticed. We also found that these cells overex-
pressed dyskerin, a conserved component of telomerase
subunit that is required for telomerase activity (p <
0.05) (Figure 2E). A similar trend was also found for tel-
omerase, although differences did not reach statistical
significance. All together, these data confirm the stem
cell identity of ALDH+ cells.
ALDH+ cells present long telomere length but similar
telomerase activity compared to ALDH- cells
We first validated the accuracy of the FISH quantifica-
tion method in NSCLC cell lines by correlating the
Figure 1 Characterization of ALDH positive population in human NSCLC cell lines. A: H1299 and H460 cells stained for Aldefluor substrate
present a positive population that is blocked by co-incubation with the specific inhibitor DEAB. B: Isolated H1299 ALDH+ cells possess self-
renewal ability as shown by their capacity to generate both ALDH+ and negative populations after 10 days of culture, while negative cells only
give rise to negative cells. C: MTT assay demonstrates a greater proliferative rate for ALDH+ cells as compared to the negative population, which
reach statistical significance at 96 h. D: Isolation of both ALDH positive and negative cells present higher colony formation efficiency in soft agar
than their negative counterpart. Data and error bars are presented as mean ± SEM; *: p < 0.05.
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lysis. We quantified telomeres from A549, H1299 and
H460 lung cell lines by both TRF and FISH techniques.
A statistically significant positive correlation (p < 0.01)
between TRF and FISH telomere analysis was observed,
allowing to calculate the telomere length based on FISH
data (see additional file 1, Supplementary figure 1D-F).
Then, both ALDH+ and ALDH- cells were sorted and
plated in equal numbers to quantify telomere length
(TL) by FISH analysis. Representative images are shown
in Figure 3A. Quantification revealed that the average
TL in H460 ALDH+ cells was 5.3 ± 2.7 Kb, which was
significantly higher (p < 0.05) than that of ALDH- cells
(4.3 ± 2.5 Kb) (Figure 3B). Similar results were obtained
for H1299 cells: 17.14 ± 5.5 Kb for ALDH+ cells in
contrast to 10.95 ± 4.1 Kb for ALDH- cells (p < 0.001).
Our data bring evidence that lung CSCs possess longer
telomeres than their differentiated counterparts.
According to the stem cell hypothesis, isolated CSCs
should give rise overtime to a large cell population of
non-CSCs, while maintaining a similar proportion of
CSCs. If this is the case, the average TL in isolated
ALDH+ cells should become similar to the average
length in the whole population. To address this issue,
ALDH+ and ALDH- cells were plated into separate cul-
ture slides and TL was measured one and two weeks
after plating. Telomeres in the ALDH- population
decreased modestly (from 4.7 kb to 4.4 kb) after 3
weeks in culture, compared to TL at day 0 (see addi-
tional file 2, Supplementary figure 2A). On the contrary,
Figure 2 ALDH positive CSC are endowed with stem cell properties. A: Representative ALDH cytometry from H460 unsorted cells grown in
presence of 10% FCS-containing medium or stem cell medium. Percentage of ALDH+ cells in H460 cell line was increased when cultured in
stem cell medium. B: Hematoxylin eosin staining of tumors engrafted after injection of ten thousand H460 ALDH sorted cells (40X). C: Tumor
incidence and volume three weeks after cell injection. D: Isolation of both SP and non-SP cells present higher colony formation efficiency in soft
agar than their negative counterpart. E: Q-RT-PCR analysis in sorted H1299 cells confirmed higher expression of ALDH and ABCG2 in ALDH+
cells. These cells also overexpress dyskerin, a component of telomerase subunit. Data and error bars are presented as mean ± SEM; *: p < 0.05,
or as indicated.
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regenerates the whole cell population) was reduced from
5.5 kb to 4.5 kb, not being statistically different from the
negative population at this point (see additional file 2,
Supplementary figure 2A).
We then used TRAP assay to measure telomerase
activity. Both ALDH+ and ALDH- cells showed similar
telomerase activity in the two cell lines analyzed (see
additional file 2, Supplementary figure 2B). Telomerase
activity of H460 cells was higher than that of H1299
cells.
The novel telomerase inhibitor MST312 preferentially
targets ALDH+ CSCs and reduces telomeric length
The antitumor effect of the telomerase inhibitor MST312
has been previously demonstrated for different cell lines
[24]. We first validated if MST312 also inhibits telomer-
ase activity in H1299 and H460 cells. We found lower tel-
omerase activity 120 h after treatment in H1299 cells
( F i g u r e3 C ) .W ea l s od e t e r m i n e db yE L I S At h et e l o m e r -
ase activity; for the untreated H1299 cells, the absorbance
was 0.827 ± 0.054 compared to 0.509 ± 0.047 for the
H1299 cells treated for 120 h (Figure 3D). We next tested
whether antitelomeric therapy would predominantly
reduce cell growth in CSCs. To verify this hypothesis,
sensitivity to MST312 was tested on ALDH-sorted H460
and H1299 populations. Treatment of sorted ALDH+/-
H460 cells induced a dose-dependent decrease in cell
survival for both populations; however, ALDH+ cells
were more sensitive than negative cells (p < 0.05) (Figure
4A). At each concentration, survival of the ALDH+ frac-
tion was approximately 20 to 25% lower than that
observed for the ALDH- population. In the case of
H1299 cells, cell growth proved to be highly affected by
MST312. At a concentration as low as 0.25 μM, the drug
induced an ~80% reduction in cell proliferation, com-
pared to untreated cells. Similarly, sorted ALDH+ H1299
cells were significantly more affected by the treatment
than ALDH- cells (Figure 4B). The use of higher doses
(0.5 μM or higher) resulted in a dramatic reduction in
cell survival (> 90%) and both ALDH+ and ALDH- cells
were equally affected (Figure 4B).
To further demonstrate that MST312 altered the num-
ber of ALDH+ cells, the whole unsorted cell population
was treated for 5 days with the compound and the num-
ber of ALDH+ cells was analyzed. Figure 4C shows a
representative FACS image in H460 cells demonstrating
an eightfold decrease in the number of ALDH+ cells
upon MST312 treatment (p < 0.05). Quantifications
show a significant decrease in the amount of ALDH+
cells after treatment for both cell lines (Figure 4D).
As shown by our previous experiments, long-term cul-
ture of ALDH+ cells repopulates both ALDH+/- cells.
To assess whether the telomerase inhibitor reduced glo-
bal TL, the unsorted whole population of H460 and
H1299 cells were cultured for 15 days with a daily low
dose of MST312 (1 μM for H460, 0.25 μM for H1299).
The average TL was significantly reduced in H460 cells:
from 4.8 ± 0.44 Kb to 3.5 ± 0.47 Kb (p < 0.001), and in
H1299 cells: from 11.33 ± 1.37 Kb to 9.05 ± 4.54 Kb (p
< 0.01).
MST312 sensitizes ALDH+ CSCs to radiotherapy-mediated
cytotoxicity in vitro
We next combined antitelomeric therapy with RT
(since CSCs are thought to be resistant to irradiation)
Figure 3 Lung tumor ALDH+ CSCs present longer telomeres. A:
FISH analysis on H460 sorted cells demonstrates that ALDH+ cells
possess longer telomeres than the negative counterpart. B:
Quantification of telomere length confirms that the ALDH+ CSC
population has longer telomeres than the negative population. C
and D: Treatment with MST312 (0.5 μM) for 120 h reduces
telomerase activity in the whole population (H1299 cells) as show
by PCR analysis (C) and ELISA (D). Data and error bars show mean ±
SEM; *: p < 0.05; **: p < 0.01; ***: p < 0.001.
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growth by ~30%), ionizing radiation (3 Gy, which
causes ~50% cell growth inhibition), and combination
of both treatments was tested on sorted ALDH+/-
H460 populations. Irradiation reduced cell viability
regardless of ALDH status, while MST312, as pre-
viously shown, decreased proliferation of ALDH+ cells
compared to the negative population (p < 0.05) (see
additional file 2, Supplemen t a r yf i g u r e2 C ) .C o m b i n a -
tion treatment further reduced cell survival especially
in the ALDH+ cell population (> 50%, in comparison
with a ~20% decrease in the ALDH- fraction). This
suggests that MST312 sensitizes the ALDH+ CSCs to
suffer a strong cytotoxicity when administered with
radiotherapy.
MST312 treatment blocks cell cycle at the G2/M phase,
increases pH2AX, p21 and p27 protein levels, and induces
apoptosis
To uncover the anti-tumor mechanism responsible for
MST312 activity, western blots were performed to mea-
sure key downstream telomerase-related signaling pro-
teins. A recent study reported that MST312 induces G2/
M cell cycle arrest and acute ATM-pathway-dependent
DNA damage in astrocytoma cells [26]. Treatment of
H460 cells with MST312 for 72 h resulted in strong
increase in the amount of pH2AX (Figure 5A). This
result was validated by immunofluorescence. In H1299
untreated cells, low levels of pH2AX and pATM were
found and signals for both proteins colocalized (Figure
5B). Administration of MST312 resulted in an increase
Figure 4 MST312 effect on both ALDH positive and negative populations. A: 96 h incubation with MST312 decreases survival of H460 cells in a
dose-dependent manner, with a greater response observed for the ALDH+ fraction. B: Similar effects are detected for H1299 cells. C and D: MST312
was administered to the whole H460 or H1299 unsorted cell populations for 5 days and ALDH+ cells were quantified by FACS analysis. D: FACS
quantifications revealed a significant reduction in ALDH+ percentage when cells were treated with MST312 (left: H460 cell line; right: H1299 cell line),
thus showing that telomerase inhibition targets the CSC population. Data and error bars are shown as mean ± SEM; *: p < 0.05; **: p < 0.01.
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Page 6 of 15Figure 5 Regulation of cell cycle distribution and ATM/pH2AX pathway by MST312. A: Western blot analysis shows an increase in pH2AX,
p21 and p27 protein levels after 72 h incubation with MST312, while hTERT, dyskerin (DKC1), pAkt and pErk remain unchanged (H460 cells). B:
Immunofluorescence for pATM (red) and pH2AX (green) in H1299 cells, before and after MST312 treatment. An increase in both pATM and
pH2AX (which colocalize) is detected as a result of the exposure to the telomerase inhibitor; DAPI counterstaining, in blue. C:
Immunoprecipitated chromatin was quantified by QPCR for the detection of telomeric sequences bound to pH2AX. Expression values were
normalized with endogenous GAPDH. TRF2 binding to telomeres was used as positive control (U: Untreated, T: MST312 Treated). D:
Representative immunoprecipitation PCR bands (U: Untreated, T: MST312 Treated). E: Cell cycle distribution underlines an arrest in the G2/M
phase after treatment, as revealed by an increasing amount of cells in this phase and a decrease in the S phase. F: 10 days treatment with
MST312 induces a dose-dependent increase in active caspase-3, H460 line. Data and error bars are presented as mean ± SEM; *: p < 0.05
compared with untreated control.
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(Figure 5B). The same results were observed in H460
line (see additional file 2, Supplementary figure 2D). To
further investigate whether MST312 was directly dama-
ging telomere DNA, a ChIP assay was performed to
determine if pH2AX binds telomere ends upon treat-
ment. H460 and H1299 cell lines were treated for 72 h
with MST312, immunoprecipitated for pH2AX and then
telomere sequences were amplified by PCR. In both cell
lines, telomere sequence was detected in treated samples
but not in untreated cells (Figure 5C and 5D). These
results show the activation of pATM/pH2AX pathway
within the telomeres by MST312.
We also checked other cell cycle and signal transduc-
tion-related proteins. An increase (of about 2-fold) in
the amount of p21 and p27 was also found (Figure 5A
and additional file 2, Supplementary figure 2E). These
changes were accompanied by a significant decrease of
cells in the S phase of the cell cycle (from 15.1 ± 0.1%
in untreated cells to 9.9 ± 1.1% in treated cells (p =
0.004)), and an increase in the G2/M phase (21.3 ±
0.5%, versus 28.1 ± 0.4% (p = 0.004)) (Figure 5E). Levels
of telomerase and dyskerin remained unchanged, con-
firming that the compound affects telomerase activity
rather than its expression. Amounts of pAkt and pErk
were not significantly modulated by the treatment. Den-
sitometric quantifications of the bands from 3 different
experiments are shown in additional file 2, Supplemen-
tary figure 2E. Although the telomerase inhibitor
stopped abruptly cell division after a short incubation
time (< 3 days in culture), apoptosis was not observed.
Nonetheless, 10 days treatment with MST312 induced a
dose-dependent increase in active caspase-3 (Figure 5F
and additional file 2, Supplementary figure 2F). This
demonstrates that apoptosis is a late event that takes
place after a cell cycle arrest for several days has
occurred.
MST312 decreases tumor size in mice by inducing
apoptosis and reducing proliferation and the number of
ALDH+ CSCs
In vivo experiments showed that MST312 significantly
reduced tumor volume by 70% (p < 0.001) as compared
with untreated mice (Figure 6A). Similar effects were
observed after RT, which shrank tumor volume by 64%
(p < 0.001) compared with controls. Combination treat-
ment resulted in a reduction of tumor volume by 78%
(p < 0.001) compared with the control group, but no
cumulative benefits were detected in vivo compared to
therapies alone (Figure 6A).
Hematoxylin-eosin staining showed tumor cells with
pyknotic nuclei in MST312-treated mice (Figure 6B). In
histological sections, the area fraction corresponding to
PCNA-positive immunostaining was 10.87 ± 3.46% for
controls and 4.57 ± 2.68% for treated mice (p < 0.001)
(see additional file 2, Supplementary figure 2G). Active
caspase-3 area fraction was increased by ~10-fold (1.01
± 0.76% in treated mice compared to 0.18 ± 0.17% in
controls, p < 0.001) (see additional file 2, Supplementary
figure 2G). Our data demonstrate that administration of
MST312 reduces tumor volume by increasing apoptosis
and inhibiting proliferation. To ascertain whether
MST312 was targeting the ALDH+ CSC population in
vivo, immunohistochemistry for ALDH (Figure 6B) and
image analysis was conducted in tumor sections as well.
Figure 6 Telomerase inhibition by MST312 reduces tumor
growth in vivo. A: Tumor growth shows strong reduction in mice
that were treated for 3 weeks with MST312 (40 mg/kg, daily).
Radiotherapy alone (10 Gys administrated locally at days 3 and 13)
produced a similar effect. No significant improvement was obtained
by combination of both therapies. B: H&E of untreated and MST312-
treated mice (upper panel) show tumor cells with pyknotic nuclei
upon treatment; immunohistochemistry for PCNA and cleaved-
caspase 3 (middle panel) demonstrate a reduction in proliferation
and increased apoptosis in mice injected with MST312, compared
to controls; immunostaining for ALDH (lower panel) also reveals a
reduction in the number of labeled cells after administration of the
telomerase inhibitor.
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highly significant reduction in mice treated with the tel-
omerase inhibitor as compared to controls (p < 0.001)
(see additional file 2, Supplementary figure 2G). At the
dose used, no significant weight loss or other signs of
toxicity were observed in any of the treated groups.
Moreover, the histological appearance of liver, intestine
and kidney was normal for mice that received MST312
(see additional file 3, Supplementary figure 3). We also
performed FISH analysis in liver sections from both
groups of animals and found no difference in telomere
length, confirming that treatment seems not to affect
normal cells (not shown).
MST312 targets CSCs in vivo and reduces significantly
telomeric length
To further verify if MST312 was preferentially targeting
ALDH+ cells in vivo, tumor cells from untreated and
treated mice were isolated and analyzed by Aldefluor.
These assays showed a significant reduction in the
number of ALDH+ cells upon treatment with MST312
in vivo: 4.1 ± 1.4% in untreated mice, versus 0.8 ± 0.21%
in treated mice (p < 0.05). Representative FACS images
and quantification results are shown in Figure 7A and
7B. All together, these novel results suggest that inhibi-
tion of telomerase function directly targets the CSC
population both in vitro and in vivo.
We next quantified TL in the ALDH+/- cell popula-
tion in vivo.T ot h i se n d ,F I C T I O N( F l u o r e s c e n c e
Immunophenotyping and Interphase Cytogenetics as a
tool for the Investigation of Neoplasms) was performed
in order to evaluate simultaneously TL (with the probe
specific for telomeres) and ALDH+ cells (by immuno-
fluorescence) (Figure 7C and 7D). Similarly to our in
vitro observations, results showed that the ALDH+
population had longer telomeres (5.37 ± 0.72 Kb) than
ALDH- cells (3.99 ± 0.11 Kb) (p < 0.001) in control
mice. We tested whether MST312 was also able to
reduce telomere length in xenotransplants. A significant
reduction of TL in ALDH+ cells after treatment (3.67 ±
Figure 7 MST312 targets ALDH+ cells in vivo and reduces their telomere length. A and B: FACS analysis and quantification of dissociated
tumors confirms, along with the immunhistochemical results, a decrease in ALDH+ cells in vivo after treatment with MST312. C: Quantification of
telomeric length in ALDH+ cells present in tumors from treated and untreated mice. A significant reduction is found in mice administered with
the antitelomeric therapy (p < 0.05). ALDH negative cells from the tumor bulk could not be accurately quantified due to massive necrosis. D:
Representative FICTION image using probes for telomeres (red), immunofluorescence for ALDH (green), and nuclear staining (DAPI, in blue).
Images show a lower intensity for telomeres in MST312-treated mice. The “M” labeled cell represents a murine fibroblast excluded from the
analysis (small nuclei and longer telomeres).
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was found (Figure 7C). Since massive necrotic areas
were found in the ALDH- tumor mass, TL could not be
accurately measured. Nonetheless, results in the ALDH+
population confirm that MST312 reduces TL in vivo.
Discussion
Cancer stem cells (CSC) are thought to be responsible
for the maintenance of the whole cancer cell population
and tumor regrowth after therapy. Although a variety of
CSC markers have been proposed, some controversy
remains over how to characterize the CSC population in
different tumor types. In this study, we used the Alde-
fluor assay (in conjunction with other methods
described for CSCs) to isolate and characterize lung
CSCs, with the goal of assessing their sensitivity to anti-
telomeric therapy. We demonstrate here that ALDH+
lung cancer stem-like cells have longer telomeres but
similar telomerase activity than the non-CSC fraction,
which make them particularly sensitive to the telomer-
ase inhibitor MST312 both in vitro and in vivo.
Many studies have shown that cancer cell lines
(including those of lung cancer) contain functional
CSCs with highly tumorigenic potential [27], which
serve as models for studying CSC properties. We first
confirmed previous findings demonstrating that ALDH
activity is a functional marker for NSCLC cell lines [28].
We have thoroughly characterized H460 and H1299
cells showing that they contain a positive ALDH fraction
that shares properties of stem cells, including self-
renewal ability, high malignant potential in vitro as well
as increased tumorigenicity in vivo. As expected, the
ALDH+ population is enriched in markers of stemness,
such as ABCG2, and telomerase. Interestingly, the SP of
these cells overlaps with the ALDH cell fraction. ALDH
+ CSCs display longer telomeres than ALDH- cells, but
similar telomerase activity. One study found similar telo-
mere length and telomerase activity in tumor initiating
prostate cells (characterized by CD44, integrin a2b1 and
CD133 markers) compared to the total cell population
[29]. A study conducted in NSCLC demonstrated higher
level of hTERT mRNA in isolated SP cells as compared
to non-SP cells, suggesting a role for telomerase func-
tion in CSCs in the renewal of the tumor population [8].
High expression and activity of telomerase have been
reported in more than 80% of tumors, including lung
cancer [30]. Most NSCLC and almost all SCLC display
substantial high levels of telomerase activity compared
to the normal lung; in addition, high hTERT mRNA
levels correlate with poor prognosis and tumor recur-
rence [30]. At the initiation of lung carcinogenesis, a
progressive reduction in telomere length has been
reported, preceding TRF1/2 overexpression and telo-
mere elongation in established tumors, as a result of
telomerase overexpression [22]. In lung cancer, the pre-
dictive value of telomere erosion and its relationship
with genetic instability are issues still needed to be ana-
lyzed in large cohorts of patients. Based on all these
data, antitelomeric therapy may be an appropriate
approach to treat lung cancer.
Different strategies targeting telomerase are currently
being tested in cancer, albeit few studies have analyzed
whether these therapies are more effective in CSCs.
These include nucleic acid-based methods to inhibit
hTERT and hTR, immunotherapy, G-quadruplex
ligands, and hTERT-targeting drugs [31]. The most
clinically advanced compound is GRN163L (Imetelstat,
Geron Corporation), which is currently in phase I clini-
cal trials for the treatment of NSCLC and breast cancer
[32]. GRN163L is a synthetic oligonucleotide comple-
mentary to the template region of hTR. This drug has
been shown to reduce NSCLC and breast cancer growth
in xenograft models [33,34].
MST312 is a small molecule that has emerged as a
promising candidate for antitelomeric therapy [24]. Pre-
vious studies in astrocytoma have shown that this telo-
merase inhibitor acts through two different mechanisms,
depending on the time of exposure [26]. Short-term
administration of the drug leads to an acute effect, with
ATM-dependent G2/M cell cycle arrest, DNA damage,
and reduced cell viability. This effect, which occurs
within 72 h after treatment, is not mediated by telomere
erosion. Long-term effects using sub-cytostatic doses of
MST312, which requires administration of the com-
pound for more than 1.5 months, leads to a significant
telomere shortening [26].
Telomere DNA damage during the acute effects sug-
gests that the telomerase complex may uncouple from
the DNA, being then recognized by the DNA-double
strand damage machinery and activation of the ATM
pathway. Increased pH2AX, which has been found in
our study and in astrocytoma [26], has been involved in
cell cycle arrest as a result of ATM activation. Impor-
tantly, we have also demonstrated here that pH2AX
binds to the telomeric DNA as a consequence of
MST312 administration. Analysis of downstream signal-
ing cascades in the present study showed increased
levels of p21 and p27. This correlates with the observa-
tion of a cytostatic effect of MST312 during the first
days of treatment, without apoptosis induction. Massive
apoptosis was detected in vitro 10 days after exposure to
the drug and this result was also corroborated in vivo in
tumor-bearing mice at the end of the experiment. These
data confirm the acute effect of MST312 on lung cancer
cells involving the ATM/pH2AX DNA-damage pathway,
leading cells to cell cycle arrest and, finally, to apoptosis.
Interestingly, Imetelstat (GRN163L), antisense hTERT
inhibition and G-cuadruplex ligands exert short-term
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resulting in cell growth inhibition and dramatic changes
in cell morphology [35-37]. This suggests novel mechan-
isms of antitelomeric therapy (unexplored yet) unrelated
to telomere attrition that will produce cancer cell
derange.
Telomeric length might determine sensitivity to
MST312, rather than telomeric activity. According to
our results, cells with longer telomeres (H1299 > H460,
and CSCs > non-CSCs) are more sensitive to MST312-
mediated cell growth inhibition. These findings fit with
previous observations, which demonstrated that telo-
mere shortening attenuates the effect of telomerase
inhibition by MST312 [38]. Although this hypothesis
should be confirmed in future studies using a larger
variety of cell lines, it is possible that cells with longer
telomeres are more prone to suffer DNA damage
because of the telomerase-DNA uncoupling. If con-
firmed, telomere length may also be an indicator of
MST312 response.
We demonstrate here for the first time that the novel
telomerase inhibitor MST312 has a potent anti-tumor
growth activity on NSCLC in vivo,w i t hm o r et h a n
70% tumor shrinkage using 40 mg/kg daily i.p. injec-
tions. Similar tumor reduction (~70%) has been found
for human glioblastoma cells xenografted into mice,
daily administered with 30 mg/kg Imetelstat [29]. His-
tologically, tumors from treated mice in our experi-
ment showed large necrotic regions, significantly lower
numbers of proliferating cells, and increased number
of apoptotic cells. Importantly, a dramatic reduction of
t h eC S Cp o p u l a t i o nw a sa l s od e t e c t e da tt h ee n do f
the in vivo treatment, as shown both by FACS analysis
for ALDH after removal of the tumor, and by immu-
nohistochemistry for ALDH. This is accompanied by a
significant reduction of the telomeric length elicited by
the drug. These results clearly show that MST312 tar-
gets preferentially CSCs in vivo and that ALDH
expression might be considered as a biomarker of
response.
Conclusions
In summary, we demonstrate herein that the ALDH+
lung cancer stem-like cell population has longer telo-
meres than non-CSCs and are highly sensitive to the
novel telomerase inhibitor MST312 in vitro and in vivo,
suggesting that this compound would mainly target the
lung CSC population. We also demonstrate that short-
term administration of MST312 switches on the ATM/
pH2AX pathway and long-term effects are typically
characterized (as expected) by telomere length shorten-
ing. Our data support the possible use of MST312 in
clinical settings against lung cancer.
Materials and methods
Cell culture, proliferation and soft agar colony formation
assay
The human NSCLC cell lines H460 and H1299 were
obtained from ATCC (Manassas, USA). Cell lines were
grown in RPMI (Lonza, Switzerland) supplemented with
10% fetal bovine serum (FBS), 100 unit/ml penicillin G
and 100 μg/ml streptomycin in a 37°C humidified 5% CO2
incubator. For spheres culture, cells (5 × 10
4 cells/mL)
were seeded in ultralow attachment dishes (Corning, USA)
and grown in serum-free DMEM/F12 medium (Lonza)
supplemented with hormone mixture B27 (Gibco, USA),
20 ng/mL EGF (Sigma-Aldrich, USA), 10 ng/mL bFGF
(Invitrogen, USA) and 1 μg/mL heparin. Fresh medium
was added to the culture every 48 h or 72 h. Spheres were
dissociated by incubating them for 5 min with StemPro
®
Accutase
® Cell Dissociation Reagent (Invitrogen).
Cell viability was determined by MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide,
Roche, Switzerland) assay. ALDH+ and ALDH- cells
were seeded in 96-well culture plates (1 × 10
4 per well)
in 100 μL of medium. 48, 72 and 96 h later, 10 μLo f
MTT (2.5 mg/ml) was added and cells were further
incubated for 4 h, followed by 100 μL of solubilization
buffer overnight. Spectrophotometric absorbance was
measured at 570 nm.
Soft agar assay for colony formation was performed by
seeding sorted cells at 10
3 cells into 0.3% agar contain-
ing RPMI and 10% FBS over 2-ml base layers (0.6%
agar). After 10 days in culture, the number of colonies
was assessed by staining with 500 μL1 0m g / m LM T T
solution. After incubation for 4 hours, 500 μLD M S O
were added, the plates were scanned, and the cell colo-
nies were counted.
ALDH staining
ALDH staining was performed with the ALDEFLUOR
kit (Stem Cell Technologies, Canada) according to the
manufacturer’s instructions. Briefly, cells were sus-
pended at 1 × 10
6 cells/ml in Aldefluor assay buffer
containing ALDH substrate (BAAA, BODIPY
® aminoa-
cetaldehyde, 1 mmol/l), with or without the specific
ALDH inhibitor diethylaminobenzaldehyde (DEAB) (1
mmol/l) for 30 min. DEAB serves as internal negative
control for each individual experiment, and allows to
distinguish between ALDH-bright (ALDHbr) cells and
cells with low ALDH activity (ALDHlow). Analysis and
sorting were conducted on a FACSAria IIu (BD, USA):
Aldefluor was excited at 488 nm and fluorescence emis-
sion was detected at 530/30. Dead cells were excluded
by gating on forward and side scatter and eliminating
the PI-positive population. The data were analyzed by
Cell Quest Pro and FlowJo (Ashland, USA).
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Cells were preincubated at 37°C for 30 min with or
without 5 μM fumitremorgin C (Sigma-Aldrich, USA)
and incubated for 90 min at 37°C with 5 μg/ml Hoechst
33342 (Sigma-Aldrich). Cells were then kept on ice for
10 min, washed, and sorted with a FACSAria IIu (BD,
USA). Hoechst dye was excited at 407 nm by violet
laser and its dual wavelengths were detected using 450/
40 (Hoechst 33342-Blue) and 620 (Hoechst 33342-Red)
filters. Dead cells were excluded as described above.
Cell cycle analysis
For cell cycle distribution analysis, adherent and floating
cells were fixed in 4% paraformaldehyde for 5 min on
ice, immersed in 70% ethanol and kept at -20°C for 30
min or until analysis. Cells were rehydrated in PBS, trea-
ted with RNase A (500 μg/ml) (Qiagen, Germany) and
stained with propidium iodide (50 μg/ml).
Quantification of mRNA by Q-RT-PCR Analysis
Purified RNA was obtained with the Qiagen RNA iso-
lation kit and cDNA was synthesized with the Super-
Script II First-Strand Synthesis System (Invitrogen).
The PCR amplification mixture contained cDNA,
SYBR Green I Master Mix buffer (Applied Biosystems),
and forward and reverse primers (20 nM each). Pri-
mers for amplification are shown in Table 1. Real time
PCR was carried out with the 7300 RT-PCR system
(Applied Biosystems, USA). Every assay was performed
in triplicate and all experiments included analysis of
G A P D Hm R N Al e v e l sa si n t e r n a ls t a n d a r d .R e l a t i v e
expression was determined by the Ct method and
levels were expressed as percentage relative to the
GAPDH mRNA levels.
Western Blot
Proteins were extracted in RIPA buffer and concentra-
tions were measured by the bicinchoninic acid method
(Pierce, USA). Total extracts were electrophoretically
fractionated on 10 or 12% Bis-Tris polyacrylamide gels
(Invitrogen) and transferred to a 0.45 μm nitrocellulose
membrane. Membranes were blocked for 1 h with 5%
nonfat dry milk in TBS-Tween and incubated overnight
at 4°C with the following primary antibodies: pH2AX,
p27, pAkt, pErk1/2 (all of them from Cell Signaling,
diluted 1:1000), p21 (Dako, 1:1000), telomerase (Novo-
castra, 1:1000), dyskerin (Sigma, 1:1000), and b-actin
(Sigma, 1:5000). Membranes were washed and incubated
with peroxidase-labeled secondary antibodies at room
temperature for 1 h. Immunoreactive bands were
detected with the Lumi-Light Western Blotting Kit
(Roche, Switzerland) and quantified with ImageJ (NIH,
USA).
Chromatin immuno-precipitation assay
ChIP (Chromatin Immuno-Precipitation) assay was per-
formed in both H460 and H1299 cell lines treated with
1 μM and 0.25 μM MST312 respectively, using EZ ChIP
kit (Millipore, USA) according to manufacturer’s
instructions. After cross-linking, cells were lysed and
sonicated (15 seconds for 3 times). Sonicated lysates
were centrifuged at 14,000 rpm at 4°C for 15 minutes
and the cleared chromatin (100 μg) was immunoprecipi-
tated with 5 μg of anti-pH2AX antibody (Cell Signaling,
USA) and incubated overnight at 4°C with rotation.
TRF2 (Telomeric Repeat-binding Factor 2) antibody
(Santa Cruz, USA) was used as positive control for the
telomere immuno-precipitation. Quantitative PCR was
performed for the detection of telomeric sequence,
whose primer sequences were (5’®3’): tel1, GGT
TTTTGAGGGTGAGGGTGAGGGTGAGGGTGAG
GGT and tel2, TCCCGACTATCCCTATCCCTATCCC
TATCCCTATCCCTA, as previously described [39].
Finally, PCR products were analyzed by agarose gel
electrophoresis.
Telomerase activity assay
Telomerase activity was measured using the Telo-
TAGGG Telomerase PCR ELISA
PLUS TRAP (Telomere
Repeat Amplification Protocol, Roche) kit, according to
the manufacturer’s instructions. The kit includes specific
telomere primers bound to biotin, which allows measur-
ing the PCR products (and the telomerase activity) by
ELISA. Briefly, 1 μg proteins were loaded into the PCR
mix. As positive control, we used an extract of the telo-
merase-positive cell line 293, and negative controls were
prepared in each case by treating cell extracts with
DNase-free RNase. To avoid the effect of Taq polymer-
ase inhibitors present in the extracts, we estimated the
Table 1 List and sequence of primers used in this
manuscript for qPCR amplification
Gene Sequence (5’->3 ’)
ALDH s TCCTGGTTATGGGCCTACAG
as CTGGCCCTGGTGGTAGAATA
ABCG2 s CACCTTATTGGCCTCAGGAA
as CCTGCTTGGAAGGCTCTATG
BMI1 s ATGCAGCTCATCCTTCTGCT
as GCATCACAGTCATTGCTGCT
DKC s TAATGTTGGCCCCATAGCAG
as CACATGGTGACAATGCATGA
hTERT s CGTGGTTTCTGTGTGGTGTC
as CCTTGTCGCCTGAGGAGTAG
MDR1 s GCTCCTGACTATGCCAAAGC
as TCTTCACCTCCAGGCTCAGT
OCT4 s ACATCAAAGCTCTGCAGAAAGAACT
as CTGAATACCTTCCCAAATAGAACCC
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[40]. Then, PCR reactions were performed using stan-
dard conditions and PCR products were run through
acrylamide gel electrophoresis at 250 V for 3 hours. The
acrylamide gel was stained with SYBR green I
(Invitrogen).
Telomere restriction fragment (TRF) analysis
Telomere length analysis by southern blot was per-
formed with Telo-TAGGG Telomere Restriction Frag-
ment kit (Roche) according to manufacturer’s
instructions. Briefly, 2 μg of nucleic DNA from each
sample were enzymatically digested and run through an
electrophoresis gel. Then, the gel was transferred over-
night and hybridized using the telomere probe provided
by the kit. Luminescence emitted by the probe was
detected by exposition to Hyperfilm ECL film (Amer-
sham Bioscience, USA). Finally, the film was scanned
and analyzed using ImageJ.
FISH analysis
To perform FISH analysis for telomeres, cells or tissues
were fixed and antigen retrieval using citrate buffer (2.1
g/L, pH 6) and heating (9 min at 95°C followed by 10
min at 85°C), followed by 30 min incubation at room
temperature with Tris Buffer Saline with 0.05% Tween
(TBS-T) and 5% Triton was used. To block unspecific
labelling, samples were incubated with 2% BSA for 30
min, dehydrated in alcohols, dried and incubated with
the Telomere PNA-Cy3 probe (Dako, Denmark). We
proceeded by co-denaturing both genomic DNA and
probes for 5 min on a hot plate at 80°C followed by
overnight hybridization at 37°C in a humidified cham-
ber. DAPI was used as a nuclear counterstain.
Animal model and treatment with the telomerase
inhibitor MST312
For the evaluation of the tumor initiating capability of
CSC, six-week-old NSG (NOD SCID IL2Rg mice from
The Jackson Laboratory, USA) were used. Mice were
maintained in a pathogen-free environment and handled
according to our institutional guidelines established for
animal care and use. Ten thousand ALDH positive or
negative sorted H460 cells were injected subcutaneously
into the flanks of the mice in a 1:1 PBS/Matrigel solu-
tion (BD). Tumor volume was measured after 3 weeks
according to the formula: V = length × (width)
2/2.
Eight-week-old male athymic mice (Harlan, Spain)
were used to test the treatment efficacy of telomerase
inhibition. 4 × 10
5 H460 cells were injected subcuta-
neously into the flanks of the mice, and animals were
randomly classified in 4 groups: controls (no treatment),
MST312-treated, radiotherapy-treated (RT), and the
combination MST312+RT. The therapeutic regimen for
MST312 consisted of daily i.p. injections (40 mg/kg) for
25 days, starting when tumors reached ~100 mm
3 in
volume. For RT, two doses of 10 Gys were locally
applied on the tumor at days 3 and 13 using a Primus
Linear Accelerator (Siemens, Germany). The same doses
and administration than those used for single therapies
were used for combination assays. Tumor volume was
periodically measured and mice were monitored care-
fully for symptoms of toxicity. All mice were sacrifized
25 days after cell injection and tissues (tumor, liver,
intestine and kidneys) were kept for immunohistochem-
ical analysis.
Tissue dissociation and analysis of ALDH+ cells
Immediately after surgical resection, tumors were
minced and digested with Collagenase/Hyaluronidase
solution (Stem Cell Technologies) for 4 h at 37°C. Cells
were then cultured for 5 h and the ALDH+ population
was analyzed. To avoid detection of murine cells we
used an anti-mouse cytokeratin (H2Kd) PE-conjugated
antibody (BD). Tumor-derived cells were incubated with
1:250 H2Kd antibody in PBS for 15 min at 37°C. Sam-
ples were then analyzed by FACS to quantify the ALDH
+ population, as described above.
Histology, immunohistochemistry, immunofluorescence
Tissues were fixed in 10% formalin, embedded in paraf-
fin and sectioned. Slides were stained with Hematoxylin
&E o s i n .F o ri m m u n o h i s t o c h e m i s t r y ,s e c t i o n sw e r e
deparaffinized and incubated for 10 min with 3.3%
H2O2 in water to block endogenous peroxidase. Antigen
retrieval was used for the detection of caspase-3, PCNA
and ALDH. Sections were incubated with 5% normal
goat serum in TBS for 30 min at room temperature.
Dilution of primary antibodies was as follows: 1:400 for
human anti-PCNA (Dako), 1:200 for human anti-ALDH
(BD)[41] and 1:200 for human anti-active caspase-3
(Cell signaling). The EnVision (Dako) system was used
to detect the bound antibodies and Harris hematoxylin
was utilized for counterstaining.
For immunofluorescence, cells or tissues were fixed,
processed according to standard procedures and incu-
bated with an anti-ALDH antibody (BD, 1:50), ATM
(Novus Biological, 1:400) and pH2AX (Cell Signaling,
1:50). Secondary antibodies conjugated with 488 Alexa
dye (for the anti-ALDH and anti-ATM antibodies), or
594 Alexa dye (for the anti-pH2AX antibody) were
applied, and DAPI (Biotium Inc, USA) was used for
nuclear counterstaining. Slides were mounted with Slow
Fade (Invitrogen) and kept at 4°C.
Image analysis and quantification
For quantification of immunohistochemistry, 60 random
images (x200) per experimental group were captured
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areas were quantified with the ImageJ software and data
were expressed as positive immunostained area with
respect to reference area.
For quantification of immunofluorescence, thirty plane
image stacks were captured 0.29 μm apart. Images were
acquired with a motorized Axioplan 2ie (Zeiss, Ger-
many) epifluorescence microscope Plan Apochromat.
Images were recorded using a CCD Photometrics mono-
chrome camera (Photometrics
® CoolSNAP™cf, Microi-
maging Application Group, USA). The Metamorph
©
software (Molecular Devices, Canada) was used to con-
trol the image acquisition.
Deconvolution, linear unmixing and image segmenta-
tion were applied following previously published proto-
cols in order to reduce the background signal and
improve quantification accuracy [42]. Briefly, software-
based image deconvolution was applied to obtain 3D
quasi-confocal sectioning from the wide field image
stacks. The model of the Point-Spread Function (PSF)
was experimentally calculated for each channel using
the TetraSpeck™ Fluorescent Microspheres (Molecular
Probes, USA) kit. Deconvolution was performed with
the Huygens software (Scientific Volume Imaging BV,
The Netherlands). Cross-talk between image channels
was estimated and eliminated using a Non Negative
Least Squares (NNLS) algorithm [43].
Telomere length was estimated as previously described
[42]. A total of 100 nuclei per mice (n = 4) were ana-
lyzed. Data are expressed as average of telomeric length.
Statistical Analysis
Results were analyzed with PRISM 4 for Macintosh
(Graphpad software Inc, USA). Comparison between
two groups was done with Student’stt e s ta n dt h ed i f -
ferences between numerous treatments were evaluated
with the analysis of covariance (ANCOVA). P values <
0.05 were considered statistically significant. For tumor
volume curves in mice, the non-parametrical Mann
Whitney U test was used. For correlation tests, we
applied the Pearson correlation coefficient and the F
and t coefficients for statistical linear regressions.
Additional material
Additional file 1: Supplementary figure 1. A: Demonstration of the
self-renewal capacity of ALDH+ H460 cells. Isolated ALDH+ cells give rise
to both ALDH+ and ALDH- populations, while negative cells are not able
to produce ALDH+ cells. B: Sorted H460 SP has significantly higher
clonogenic capacity than non-SP cells. C: Demonstration that the H1299
SP overlaps with the ALDH+ populations. 27.3% of the SP corresponded
to ALDH+ cells, whereas only 3.48% of non-SP were ALDH+. D:
Representative FISH images from H460, A549 and H1299 unsorted cell
lines used for the telomere quantification. E: Telomere length analysis by
TRF; left, DNA ladder; right, H460, A549 and H1299 genomic DNA
digested and hybridized with a telomeric specific probe. F: Correlation
graph demonstrating the accuracy of extrapolation between image
arbitrary units (FISH signals) and telomere length measured by TRF. ***: p
< 0.001.
Additional file 2: Supplementary figure 2. A: ALDH+ and ALDH- cells
were plated into separate culture slides and telomeric length was
measured one and two weeks after plating. Telomeres in the ALDH+
population reached a similar length than that found in the negative
fraction. This is likely due to the generation by ALDH+ cells of a majority
of ALDH- population overtime, which supports the self-renewal capacity
of these cells. B: Telomerase activity in both ALDH+/- cells. C: MST312
sensitizes ALDH+ cells to radiotherapy-induced cytotoxicity in vitro.
Radiotherapy (RAD) alone causes a comparable decrease in cell survival
of both ALDH positive and negative populations in H460 cells.
Administration of MST312 sensitizes cells to irradiation-dependent
cytotoxicity. D: Immunofluorescence for pATM (red) and pH2AX (green)
in H460 cells, before and after MST312 treatment. An increase in both
pATM and pH2AX (which co-localize) is detected as a result of the
exposure to the telomerase inhibitor. E: Densitometric quantification of
the bands from western blots of proteins related to cell cycle and DNA
damage signaling cascades in untreated and MST312-treated cells. Three
western blot analyses were quantified by densitometry; b-actin was used
as housekeeping protein and data are presented in fold changes
compared to the untreated group. Increase in pH2AX, p21 and p27
protein levels after 72 h incubation with MST312 was observed. No
changes were found for hTERT, dyskerin (DKC1), pAkt and pErk. F: 10
days treatment with MST312 induces a dose-dependent increase in
active caspase-3, H1299 cell line. G: Quantification of PCNA, cleaved-
caspase 3 and ALDH staining by image analysis in tumor sections. *: p <
0.05; **: p < 0.01; ***: p < 0.001 compared with control.
Additional file 3: Supplementary figure 3. Histological appearance of
liver, intestine and kidney in mice that received MST312 (treated) in
comparison to controls. No significant changes are appreciated between
both groups.
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